retatrutide poland Retatrutide: Promising Weight Loss Medication in Phase 3 Trials | Sunando Roy Choudhury posted on the topic Retatrutide (LY3437943) | GCGR/GLP-1R/GIPR Agonist
Description
| 40 comments on LinkedIn
Experiencing acid reflux on GLP-1 medications
Compounded GLP-1 now eligible We now accept HFA/FSA
Today, we announced our investigational glucagon/GLP-1 dual receptor agonist achieved key measures of success at 48 weeks in our IMPACT Phase 2b trial and recent interactions with the FDA have resulted in alignment on the parameters for a registrational Phase 3 trial
